Crossmark

Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial

Crossref DOI link: https://doi.org/10.1038/s41598-025-22554-6

Published Online: 2025-11-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sangiorgi, Luca https://orcid.org/0000-0003-3658-1209
Conrad, Ernest U. https://orcid.org/0000-0002-0485-907X
Shih, Fei https://orcid.org/0009-0006-5821-1267
Strahs, Andrew

Feldman, David S. https://orcid.org/0000-0001-9190-6083
License Information

Text and Data Mining valid from 2025-11-04

Version of Record valid from 2025-11-04
More Information

Article History

Received: 5 February 2025

Accepted: 29 September 2025

First Online: 4 November 2025

Declarations

:

: LS, EUC and DSF: no conflicts of interest to declare. FS and AS: Employees and stockholders (received as part of their employee compensation) of Ipsen.

: The trial was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below